MIRM
8:05 AM
News Updates
Thu, May 21, 2026
1 updatesThu, May 14, 2026
1 updatesMIRM
4:01 PM
Tue, May 12, 2026
3 updatesWed, May 6, 2026
1 updatesMon, May 4, 2026
1 updatesMIRM
8:00 AM
Sun, May 3, 2026
1 updatesMIRM
5:00 PM
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Results CallCall Mon, May 4, 2026mirumpharma.com
Wed, Apr 29, 2026
1 updatesMon, Apr 27, 2026
1 updatesMIRM
8:00 AM
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Trial Results • Phase 2mirumpharma.com
Mon, Apr 13, 2026
1 updatesMIRM
4:01 PM
Mon, Mar 16, 2026
1 updatesMIRM
8:00 AM
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Enrollment • Phase 3mirumpharma.com
Thu, Mar 12, 2026
1 updatesMIRM
5:30 PM
Thu, Mar 5, 2026
1 updatesMIRM
8:00 AM
Mirum Pharmaceuticals Completes AZURE-1 Enrollment and AZURE-4 Screening in Phase 3 Program of brelovitug in Chronic Hepatitis Delta Virus
Enrollment • Phase 3mirumpharma.com